Systematic review: Preventive and therapeutic applications of metformin in liver disease

World Journal of Hepatology

Volumn 7, Issue 12, 2015, Pages 1652-1659

  Bhat, Aparna ^a   Sebastiani, Giada ^a   Bhat, Mamatha ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Chemoprevention; Hepatitis; Hepatocellular carcinoma; Metformin; Non alcoholic fatty liver disease

Indexed keywords

EID: 84934285880     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i12.1652     Document Type: Short Survey

References (64)

1. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, De Berardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752 [PMID: 17638885 DOI: 10.1158/0008-5472.CAN-06-4447].
2. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes 2011; 3: 320-327 [PMID: 21631893 DOI: 10.1111/j.1753-0407.2011.00119.x].
3. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507-511 [PMID: 18360697 DOI: 10.3892/ijmm. 21.4.507].
4. Pawalowska M, Markowska A. The influence of metformin in the etiology of selected cancers. Contemp Oncol (Pozn) 2012; 16: 223-229 [PMID: 23788884 DOI: 10.5114/wo.2012.29289].
5. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013; 123: 3693-3700 [PMID: 23999444 DOI: 10.1172/JCI67232].
6. Rosilio C, Ben-Sahra I, Bost F, Peyron JF. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer Lett 2014; 346: 188-196 [PMID: 24462823 DOI: 10.1016/j. canlet. 2014.01.006].
7. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575 [PMID: 19629071 DOI: 10.1038/nrc2676].
8. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: taking away the candy for cancer? Eur J Cancer 2010; 46: 2369-2380 [PMID: 20656475 DOI: 10.1016/j.ejca.2010.06.012].
9. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012; 133: 108-115 [PMID: 21924289 DOI: 10.1016/j.pharmthera.2011.09.004].
10. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19: 1649-1654 [PMID: 24185692 DOI: 10.1038/nm.3372].
11. Shaw RJ. Metformin trims fats to restore insulin sensitivity. Nat Med 2013; 19: 1570-1572 [PMID: 24309653 DOI: 10.1038/nm.3414].
12. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-388 [PMID: 21459323 DOI: 10.1016/j.cmet.2011.03.009].
13. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012; 2012: 716404 [PMID: 22194737 DOI: 10.1155/2012/716404].
14. Huypens P, Quartier E, Pipeleers D, Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 2005; 518: 90-95 [PMID: 16039647 DOI: 10.1016/j.ejphar.2005.06.016].
15. Zhang S, Liu X, Brickman WJ, Christoffel KK, Zimmerman D, Tsai HJ, Wang G, Wang B, Li Z, Tang G, Liu X, Yang J, Xu X, Wang X. Association of plasma leptin concentrations with adiposity measurements in rural Chinese adolescents. J Clin Endocrinol Metab 2009; 94: 3497-3504 [PMID: 19584182 DOI: 10.1210/jc.2009-1060].
16. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305 [PMID: 15849206 DOI: 10.1136/bmj.38415.708634.F7].
17. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-1625 [PMID: 19564453 DOI: 10.2337/dc08-2175].
18. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010; 53: 1631-1637 [PMID: 20407744 DOI: 10.1007/s00125-010-1750-8].
19. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923 [PMID: 12668987 DOI: 10.1053/jhep.2003.50161].
20. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501 [PMID: 9765002 DOI: 10.1016/S0168-8278(98)80073-1].
21. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085(98)70599-2].
22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001].
23. Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther 2014; 31: 30-43 [PMID: 24385405 DOI: 10.1007/s12325-013-008 4-6].
24. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010; 34: 1255-1264 [PMID: 20179669 DOI: 10.1038/ijo.2010.40].
25. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-28 [PMID: 15225167 DOI: 10.1111/j.1365-2036.2004.02025.x].
26. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182 [PMID: 18945255 DOI: 10.1111/j.1365-2036.2008.03869. x].
27. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-165 [PMID: 18197877 DOI: 10.1111/j.1872-034X.2007.00215.x].
28. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol 2009; 2: 157-163 [PMID: 21180541 DOI: 10.1177/1 756283X09105462].
29. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544 [PMID: 14987322 DOI: 10.1111/j. 1365-2 036.2004.01888.x].
30. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-860 [PMID: 19811343 DOI: 10.1080/00365520902845268].
31. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30: 1168-1176 [PMID: 18640473 DOI: 10.1016/j.clinthera.2008.06.012].
32. Kumar M, Choudhury A, Manglik N, Hissar S, Rastogi A, Sakhuja P, Sarin SK. Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol 2009; 104: 76-82 [PMID: 19098853 DOI: 10.1038/ajg.2008.9].
33. Lee JG, Lee S, Kim YJ, Cho BM, Park JS, Kim HH, Cheong J, Jeong DW, Lee YH, Cho YH, Bae MJ, Choi EJ. Association of chronic viral hepatitis B with insulin resistance. World J Gastroenterol 2012; 18: 6120-6126 [PMID: 23155341 DOI: 10.3748/wjg.v18.i42.6120].
34. Xun YH, Zhang YJ, Pan QC, Mao RC, Qin YL, Liu HY, Zhang YM, Yu YS, Tang ZH, Lu MJ, Zang GQ, Zhang JM. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. J Viral Hepat 2014; 21: 597-603 [PMID: 24164660 DOI: 10.1111/jvh.12187].
35. Hsu CS, Hsu SJ, Lin HH, Tseng TC, Wang CC, Chen DS, Kao JH. A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin. J Formos Med Assoc 2014; 113: 716-721 [PMID: 24974131 DOI: 10.1016/j.jfma.2014.05.007].
36. Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol 2011; 26 Suppl 1: 96-101 [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542. x].
37. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702-1708 [PMID: 19845037 DOI: 10.1002/hep.23206].
38. Sharifi AH, Mohammadi M, Fakharzadeh E, Zamini H, Zaer-Rezaee H, Jabbari H, Merat S. Efficacy of adding metformin to pegylated interferon and ribavirin in treatment naïve patients with chronic hepatitis C: a randomized double-blind controlled trial. Middle East J Dig Dis 2014; 6: 13-17 [PMID: 24829699].
39. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, Grando-Lemaire V, Vicaut E, Trinchet JC, Beaugrand M. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-2608 [PMID: 21752887 DOI: 10.1210/jc.2010-2415].
40. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011; 9: 33 [DOI: 10.1186/1741-7015-9-33].
41. Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology 2013; 58: 810-818 [PMID: 23408390 DOI: 10.1002/hep.26323].
42. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 [PMID: 10647931 DOI: 10.1016/S0092-8674(00)8168 3-9].
43. Cheng J, Huang T, Li Y, Guo Y, Zhu Y, Wang Q, Tan X, Chen W, Zhang Y, Cheng W, Yamamoto T, Jing X, Huang J. AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS One 2014; 9: e93256 [PMID: 24709998 DOI: 10.1371/journal.pone.0093256].
44. Xiong Y, Lu QJ, Zhao J, Wu GY. Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev 2012; 13: 3275-3279 [PMID: 22994747].
45. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983, 1983.e1-11 [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008].
46. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J, Pan Y. In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 2012; 42: 922-933 [PMID: 22524458 DOI: 10.1111/j.1872-034X.2012.01007.x].
47. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, Kobayashi M, Morishita A, Kobara H, Mori H, Yoneyama H, Deguchi A, Himoto T, Kurokohchi K, Okano K, Suzuki Y, Murao K, Masaki T. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2014; 45: 322-332 [PMID: 24806290].
48. Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012; 5: 544-552 [PMID: 22467080 DOI: 10.1158/1940-6207.CAPR-11-0228].
49. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615 [PMID: 22773548 DOI: 10.1136/gutjnl-2011-301708].
50. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506-2511 [PMID: 19469001 DOI: 10.3748/wjg.15.2506].
51. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20 [PMID: 21241523 DOI: 10.1186/1471-2407-11-20].
52. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116: 1938-1946 [PMID: 20166205 DOI: 10.1002/cncr.24982].
53. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891; quiz 892 [PMID: 23381014 DOI: 10.1038/ajg.2013.5].
54. Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87 [PMID: 23137049 DOI: 10.3109/00365521.2012.719926].
55. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52 [PMID: 22085817 DOI: 10.1038/ajg.2011.384].
56. Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3025-3032 [PMID: 20572306 DOI: 10.3748/wjg.v16.i24.3025].
57. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-758 [PMID: 20331505 DOI: 10.1111/j.1478-3231.2010.02223.x].
58. Chen CI, Kuan CF, Fang YA, Liu SH, Liu JC, Wu LL, Chang CJ, Yang HC, Hwang J, Miser JS, Wu SY. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) 2015; 94: e462 [PMID: 25674734 DOI: 10.1097/MD.0000000000000462].
59. Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20: 15750-15755 [PMID: 25400459 DOI: 10.3748/wjg.v20.i42.15750].
60. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011; 26: 858-865 [PMID: 21251068 DOI: 10.1111/j. 1440-1746.2 011.06664.x].
61. Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Therneau TM, Roberts LR, Chaiteerakij R. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60: 2008-2016 [PMID: 24798175 DOI: 10.1002/hep.27199].
62. McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DR. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) 2011; 13: 309-319 [PMID: 21492330 DOI: 10.1111/j. 1477-2574.2010.00286.x].
63. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM, Roberts LR. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013; 57: 648-655 [PMID: 23055147 DOI: 10.1002/hep.26092].
64. Ling S, Feng T, Ke Q, Fan N, Li L, Li Z, Dong C, Wang C, Xu F, Li Y, Wang L. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 2014; 31: 2611-2618 [PMID: 24788596 DOI: 10.3892/or.2014.3151].